Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cystemustine
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Intravenous, Intraperitoneal (preclinical)
01
Overview
Cystemustine is a **chloroethyl-nitrosourea derivative** related to alkylating agents, specifically **N'-(2-chloroethyl)-N-[2-(methylsulfonyl)ethyl]-N'-nitrosourea** (CMSO2EN2)[1][5]. It functions primarily as a DNA-alkylating agent, exerting cytotoxic and potentially antineoplastic effects by causing DNA cross-linking and carbamoylation[1]. Cystemustine’s primary mechanism involves induction of DNA damage in rapidly dividing cells, and it has been investigated in preclinical cancer models, particularly for melanoma and colon cancers[3].
- Other names
- N'-(2-chloroethyl)-N-[2-(methylsulfonyl)ethyl]-N'-nitrosoureaCMSO2EN2CMSO-2EN2CMSO 2EN2
02
Targets
DNA
Beyond the preview
Go deeper on cystemustine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cystemustine.